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EFFECTS OF INHIBITION OF 
COMPLEMENT ACTIVATION 
USING RECOMBINANT 
SOLUBLE COMPLEMENT 
RECEPTOR 1 ON 
NEUTROPHIL CD11B/CD18 
AND L-SELECTIN 
EXPRESSION AND RELEASE 
OF INTERLEUKIN-8 AND 
ELASTASE IN SIMULATED 
CARDIOPULMONARY 
BYPASS 
The inflammatory response to cardiopulmonary bypass includes activation 
of complement and induction of several neutrophil activation pathways. A 
recombinant soluble form of complement receptor 1 was used as a specific 
inhibitor of complement activation in simulated cardiopulmonary bypass 
circuits. Substantial complement activation was observed in these circuits 
with progressive accumulation of both plasma C3a and terminal comple- 
ment complex. Soluble complement receptor 1 resulted in a significant 
reduction in C3a levels (p < 0.01) but did not inhibit terminal complement 
complex generation. A marked rise in neutrophil CDllb/CD18 expression, 
simultaneous loss of L-selectin expression, and a progressive accumulation 
of plasma elastase-oq-antitrypsin occurred and were not affected by soluble 
complement receptor. However, generation of interleukin-8 in the circuits 
was inhibited (p < 0.05) by pretreatment with soluble complement receptor. 
These data suggest that changes in neutrophil activation seen during 
cardiopulmonary bypass may not be induced directly by anaphylatoxin 
generation. (J THORAC CARDIOVASC SURG 1996;111:451-9) 
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A ctivation of complement during cardiopulmo- nary bypass has been proposed as an important 
mediator of the adverse ffects of cardiopulmonary 
bypass, particularly because of the known stimula- 
tory effects of products of complement activation on 
neutrophils. Although the importance of comple- 
ment activation is controversial, 1'2 inhibition of 
complement activation during experimental cardio- 
pulmonary bypass can attenuate cardiopulmonary 
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bypass-induced lung injury and endothelial dysfunc- 
tion. 3 Activation of both classic and alternative 
pathways occurs in cardiopulmonary bypass, and 
both culminate in cleavage of C3 and C5 with the 
generation of the anaphylatoxins C3a and C5a, 
which can activate neutrophils, enhancing chemo- 
tactic activity, respiratory burst, and degranulation, 
as well as inducing changes in adhesion molecule 
expression. 4 Although C5a is the more potent neu- 
trophil stimulatory factor, it is rapidly bound to 
specific receptors expressed by neutrophils 5 and is 
thus removed from the circulation, which thereby 
restricts its value as an index of complement activa- 
tion. The cleavage of C5 also results in the activation 
of the membrane attack pathway and the deposition 
of C5b-9 in the target cell membrane, which may 
result in cell lysis or cell activation. A soluble form 
of the complex, SC5b-9, is also formed as a by- 
product of the pathway and released into the 
plasma. It is relatively stable and therefore a good 
marker of activation of the terminal complement 
pathway. 6 
There is evidence that neutrophils mediate micro- 
vascular injury after cardiopulmonary bypass. 7-9 
Their adhesion to endothelium is a prerequisite for 
this. 1° An initial tumbling or rolling adhesion medi- 
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ated by selectin adhesion molecules expressed by 
both unactivated neutrophils (L-selectin) 11 and en- 
dothelial cells is followed by an activation step 
during which the neutrophil changes from a spher- 
ical, smooth shape to an elongated, bipolar structure 
leading to more avid adhesion mediated by leuko- 
cyte integrins (CDlla/CD18 and CDllb/CD18). 12 
Numerous chemotactic agents, including C5a and 
interleukin-8 (IL-8), induce a rapid cleavage of the 
extracellular domain of L-selectin and a simulta- 
neous rapid increase in the surface expression of 
CDllb/CD18 by mobilization of preformed granu- 
lar stores. ~3 The exact functional significance of 
these changes remains uncertain but they are sensi- 
tive markers of neutrophi] activation. 
Elastase, an endopeptidase (protease) released by 
neutrophils, is a component of the nonoxidative 
microbicidal response. The enzyme can degrade 
several elements of the endothelial extracellular 
matrix and thus may contribute to neutrophil-in- 
duced endothelial injury. TM 15 Free elastase is rap- 
idly bound to the plasma endopeptidase inhibitor 
%-antitrypsin to form a stable complex, and ele- 
vated levels of this can be detected in the blood of 
patients with acute inflammatory states 16 and have 
been demonstrated in cardiopulmonary b pass both 
in v ivo  17' 18 and in simulated circuits. 19' 2o 
IL-8 is member of a large family of related 
cytokines and has potent and specific effects on 
neutrophils. 21 In addition to chemotactic activity, 
IL-8 can induce enzyme release and the respiratory 
burst and cause changes in adhesion to endothe- 
lium. IL-8 has been shown bound to endothelium in
immunohistochemical studies 22 and may regulate 
neutrophil transendothelial migration. 23' 24 Subcuta- 
neous injection of the cytokine induces a rapid and 
specific neutrophil infiltration and associated endo- 
thelial injury. 25 
In the context of cardiopulmonary b pass, it has 
been widely stated that the adverse effects of 
complement activation are mediated via neutrophil 
activation. 26-28 In this study we examined the hy- 
pothesis that cardiopulmonary b pass-induced com- 
plement activation contributes to the induction of 
changes in neutrophil adhesive properties, to the 
release of neutrophil elastase, and to the generation 
of IL-8. 
Methods 
The study was approved by the ethics committee of the 
Royal Brompton National Heart and Lung Hospital. All 
volunteers gave informed consent. 
Cardiopulmonary bypass circuits. Ten complete x- 
periments were done and no samples were lost during 
collection or analysis. Circuits consisted of an oxygenator 
(model Wm Harvey It1700, CR Bard Inc., Tewksbury, 
Mass.)and reservoir connected by standard 3/s-inch polD 
vinyl chloride (PVC) tubing to an occlusive roller pump. 
The oxygenators were connected via a water circuit to a 
thermostatic heat exchanger and had filtered air passed 
through the oxygen port at 2 L/rain throughout the 
experiment. Four hundred milliliters of fresh human 
blood, obtained by venipuncture from healthy adult male 
volunteers, was mixed immediately with 600 ml of Hart- 
mann's olution and used to prime the circuit. Anticoag- 
ulation was achieved with heparin to a final concentration 
of 4 units/ml prime. A flow rate of 3 L/rain was maintained 
for 2 hours at 37 ° C. A further 30 ml of blood was mixed 
with 45 ml of Hartmann's solution, identically anticoagu- 
lated, and used to prime a closed loop of identical circuit 
tubing , Which was left static in a water bath at 37 ° C. In 
half the experiments a freshly reconstituted solution of 
recombinant soluble complement receptor 1(sCR1) (final 
concentration 50txg/ml) was added to the collection bag 
and syringe before venipuncture. In the remainder recon- 
stitution solvent only was added. Previous pilot studies 
had shown that this concentration produced near maximal 
inhibition of C3a generation i similar circuits (data not 
shown). 
Samples were taken immediately after hemodilution 
and 2, 30, 60, 90, and 120 minutes after commencement of 
circulation from both circuits and static loops. Blood 
anticoagulated with ethylenediaminetetraacetic acid was 
analyzed for hematocrit concentration, leukocyte count 
(Coulter counter), and manual leukocyte differential nd 
centrifuged at 4 ° C; the plasma was separated and stored 
at -70 ° C for analysis of IL-8, elastase-a~-antitrypsin, 
C3a, and terminal complement complex (TCC). A further 
four aliquots from each sample were anticoagulated with 
a 20 u/ml concentration f preservative-free heparin and 
cells stained immediately with the use of direct immuno- 
fluorescence. 
Direct immunofluorescence staining. Four 25 /xl ali- 
quots of blood from each sample were incubated for 10 
minutes at room temperature with saturating concentra- 
tions of one each of the following four ftuorochrome- 
conjugated mouse immunogl0bulin G1 anti-human mono- 
clonai antibodies: anti-CDlla (25-3-1) (The Binding Site, 
Birmingham, United Kingdom), anti-CD!lb (44) (Cym- 
bus, Southampton, United Kingdom), anti-L-selectin 
(TQ1) (Coulter, Lut0n, United Kingdom), and a negative 
control antibody directed against a nonhuman epitope 
(X927) (Dako, High Wycombe, United Kingdom) as 
previously described. 29Erythrocytes were then lysed with 
fluorescence-activated cell sorter lysing solution (Becton 
Dickinson, Oxford, United Kingdom), and samples were 
washed with Hanks' balanced salt solution without cal- 
cium, magnesium, or phenol red (Gibco, Paisley, United 
Kingdom), resuspended in fixative (1% formaldehyde, 2% 
glucose in phosphate buffered saline [PBS]), and held at 4 ° 
C in the dark until flow cytometry. 
Flow cytometry. Flow cytometry was done with a Bec- 
ton-Dickinson FACScan instrument. Green and red am- 
plifier gains were calibrated before each experiment with 
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beads (Flow Cytometry Standards Corp., Research Trian- 
gle Park, N.C.) to ensure that relative fluorescence values 
were comparable between experiments and to monitor 
cytometer performance. Light scatter data amplifiers were 
set in linear mode whereas fluorescence detectors were set 
in (4 decade) logarithmic mode. Forward and orthogonal 
light scatter and green and red fluorescence data from 
2000 events (leukocytes) from each sample were then 
acquired. Data were analyzed with the use of Datamate 
flow cytometry software (Applied Cytometry Systems , 
Sheffield, United Kingdom). For each experiment, a new 
analysis gate was created and verified to encompass the 
granulocyte cluster on the forward/orthogonal scatter dot 
plots for all samples. A median channel number was 
computed for each distinct population on the fluorescence 
histogram of each gated population (Fig. 1) and converted 
mathematically into a relative fluorescence value by 
the following formula: relative fluorescence = 
antiloglo(channel number/number of channels per de- 
cade). These values, with the relevant negative control 
antibody value subtracted in each case, were then used to 
represent the level of expression of the epitopes under 
study on the surface of the neutrophils. 
Immunosorbent assays for TCC, elastase-al-antitry p- 
sin, and IL-8. TCC was assayed with use of a monoclonal 
capture antibody (B7) that recognizes a neo-epitope on 
the complex not expressed by the component proteins 
before assembly. 3°PVC 96-well plates (Flow Laborato- 
ries, Herts, United Kingdom) were coated with antibody 
B7 (10 /zg/ml) in carbonate/bicarbonate buffer (pH 9.6) 
for 16 hours at 4 ° C or for 2 hours at 37 ° C, washed, and 
then blocked for 1 hour. Standards prepared from dilu- 
tions of fully inulin-activated normal human serum and 
samples, diluted 1 in 100, were added and incubated for 2 
hours. Wells were then washed and incubated with rabbit 
anti-S protein IgG (in-house), diluted 1 in 2000, for 1.5 
hours. Wells were then washed and incubated with donkey 
anti-rabbit IgG conjugated to horseradish peroxidase 
(Jackson Immunoresearch Labs, West Grove, Pa.) diluted 
1 in 5000, for 1 hour. After further washes, a substrate 
solution containing 0.7 mg/ml o-phenylenediamine dihy- 
drochloride in a solution of 0.05% H202, 0.1 mol/L citric 
acid, and 0.2 mol/L NazHPO 4 was added; the reaction was 
stopped after 2 to 5 minutes with 10% H2SO4, and plates 
were read with use of a spectrophotometer (Titertek 
Multiscan MCC/340, Flow ICN, Rickmansworth, United 
Kingdom) set to 492 nm. PBS with 0.1% polysorbate 20 
(Tween 20, BDH, Poole, United Kingdom) was used for 
all washes, with 1% bovine serum albumin (Sigma, Poole, 
United Kingdom) added for dilution of samples, stan- 
dards, second and third antisera, and blocking steps. 
Incubation and blocking steps were done at 37 ° C. All 
samples were assayed in triplicate and percentage activa- 
tion calculated from a standard curve prepared concur- 
rently with each assay. The percentage activation in each 
sample was converted to micrograms per milliliter TCC 
using a conversion factor of 1% activation = 2.2/xg/ml, 
derived from Hugo, Kramer, and Bhakdi. 3~ 
Elastase-cq-antitrypsin concentrations were measured 
by an assay modified after Brower and Harpel. 32 PVC 
96-well plates (Greiner, Frickenhausen, Germany) were 
coated with sheep anti-human elastase (The Binding Site) 
(15 mg/ml) in carbonate/bicarbonate buffer (pH 9.6) for 
24 hours, washed, and blocked for 30 minutes. Standards 
and samples, diluted 1 in 100 to 1 in 500, were added and 
incubated for 2 hours. Wells were then washed and 
incubated with peroxidase-conjugated sheep anti-human 
cq-antitrypsin (The Binding Site), diluted 1 in 1000, for 1 
hour. After further washes, asubstrate solution containing 
a 0.5 mg/ml concentration of o-phenylenediamine dihy- 
drochloride in a solution of 0.05% H202, 0.1 mo!/L citric 
acid, and 0.2 mol/L Na2HPO 4 was added; the reaction was 
stopped after 20 minutes with 4 mol/L H2SO4, and plates 
were read with use of a spectrophotometer (Titertek 
Multiscan; Flow ICN) set to 492 nm. PBS with 0.05% 
polysorbate 20 (Tween 20, BDH) was used for all washes 
and dilution of samples, standards, and second antisera, 
with 1% bovine serum albumin (BDH) added for block- 
ing. Coating, incubation, and blocking steps were done at 
room temperature. All samples were assayed in duplicate 
and concentrations calculated from a standard curve 
prepared concurrently with each assay. 
Assays for IL-8 were done with the use of kits (Quan- 
tikine, R & D Systems, Minneapolis, Minn.) according to 
the manufacturer's instructions. Samples were diluted i in 
2 in the appropriate supplied diluent and incubated for 2 
hours in wells coated with monoclonal anti-cytokine anti- 
body. Wells were washed and then incubated for 2 hours 
with polyclonal anti-cytokine antibody conjugated to 
horseradish peroxidase. After further washes, a substrate 
solution containing tetramethylbenzidine and H20 2 was 
added; the reaction was stopped after 20 minutes with 2 
mol/g H2SO 4 and plates were read with use of a spectro- 
photometer (Dynatech MR4000, Billingshurst, United 
Kingdom) set to 450 nm with wavelength correction set to 
570 nm. The supplied wash buffer was used for all washes. 
Incubation steps were done at room temperature. All 
samples were assayed in duplicate and concentrations 
calculated from a standard curve prepared concurrently 
with each assay. 
The lower limit of these assays was defined, in all cases, 
as that concentration that corresponded to an optical 
density of 1.5 times the mean optical density of the blank 
wells of the plate. 
Radioimmunoassays for C3a. Assays were done with 
the use of [125I]radioimmunoassay kits obtained from 
Amersham International (Alysbury, Bucks, United King- 
dom). Briefly, the assay is based on competition between 
the unknown C3a and C3a desArg in the sample and 
125I-labeled C3a desArg for a limited number of binding 
sites on a specific rabbit anti-C3a antibody. The antibody- 
bound fraction is reacted with a second antibody (goat 
anti-rabbit) and separated by centrifugation at2000 g. The 
radioactivity in the pellet is measured with a gamma 
scintillation counter and the concentration of unlabeled 
C3a and C3a desArg in the sample determined by inter- 
polation from a standard curve. The working range for the 
assay is 40 to 100 ng/ml: samples that contained more than 
this concentration were diluted appropriately and reas- 
sayed. The assay shows less than 1% cross-reactivity with 
C4a desArg and C5a desArg. The intraassay variation lies 
between 3% and 9% depending on the concentration of
C3a in the sample. 
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Fig. 1. Fluorescence histograms of gated granulocytes 
stained with phycoerythrin-conjugated anti-L-selectin in 
blood samples taken after 2 (aL 60 (b), and 120 (e) 
minutes of circulation in oxygenator circuit. Slight de- 
crease in fluorescence ofmain population of cells (right) is 
observed with time whereas new population with low 
fluorescence emerges (left) at expense of main population. 
Note that fluorescence is shown on logarithmic scale. 
Statistics. Summary measures tatistics were used to 
incorporate the values from the multiple measurements 
made at different imes without making multiple compar- 
isons. 
Differences between circulating and static blood. To as- 
sess the significance of differences in the various param- 
eters under study between paired samples taken simulta- 
neously from circuits and static loops, the difference was 
calculated for each time point in an experiment and 
plotted against ime. For each set of points corresponding 
to a single experiment a regression line passing through 
the origin (because the difference at time zero was always 
nil) was fitted. Where the slopes of these lines are, on 
average, zero, this suggests, for the data observed in this 
study, that no difference xists between values for circu- 
lating and static blood. Slopes were calculated with the 
formula b = Exiyi/Ex 2, where b is the slope, x is the time 
value, y is the parameter value (e.g., the difference in 
CDl lb expression), and i equals 1 . . . . .  n representing 
serial measurements. A one-sample t test was then used to 
test the hypothesis that the slopes were zero on average. 
Where changes in the parameter under study were de- 
tected only at one point (e.g., IL-8) a paired t test was 
done comparing the differences between the circulating 
and static values for each experiment at that time. sCR1- 
treated and sCRl-untreated groups were assessed sepa- 
rately. 
Effects of sCRL To assess the effects of sCR1 on the 
parameters under investigation first-order regression lines 
(least squares) were fitted to plots of measured values 
against ime. In this instance circulating values and static 
values were assessed separately because of the likelihood 
that sCR1 could be affecting changes in both, so that such 
effects could be masked in an analysis of the differences. If
sCR1 was having no effect, the slopes of these lines would, 
on average, be identical in experiments with and without 
sCR1. An unpaired t test was then used to test this 
hypothesis. Where changes in the parameter under study 
were detected only at one point (i.e., IL-8) an unpaired t 
test was done instead on the two groups of values at that 
time. In all other cases comparisons between individual 
points were not made. 
Results 
A large progressive rise in plasma C3a level was 
observed in the circuits with time (Fig. 2). A smaller 
rise (t = 5.31,p < 0.001) was also observed in static 
control loops. These rises were both markedly re- 
duced by treatment with sCR1 (t = 3.69 and 6.88, 
respectively; both p < 0.01). A rise in plasma TCC 
level was also observed in the circuits, although not 
in the static control loops (Fig. 3). Treatment with 
sCR1 had no effect on this rise in plasma TCC level. 
Hematocrit  concentrations and neutrophil counts 
fell to about 40% of values in undiluted venous 
blood when the blood was added to the priming 
solution and values remained at this level through- 
out the experiments in both circuits and static 
control loops. This was not altered by sCR1 treat- 
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Fig. 2. Plasma concentrations of C3a in cardiopulmonary 
bypass circuits. Samples were taken at 30-minute intervals. 
Results from control loops of circuit ubing held static are 
shown on right-hand side. Data are shown as mean plus or 
minus 2 standard errors. Treatment with sCR1 (50/xg/ml) 
greatly reduced C3a generation (p < 0.01). 
ment (data not shown). No significant change in 
neutrophil CD11a/CD18 expression was observed 
under any conditions (data not shown). A marked 
homogeneous and progressive rise in neutrophil 
CDl lb/CD18 expression occurred in the circuits 
and contrasted with significantly smaller ises in the 
static control loops. This increase in neutrophil 
CD l lb  expression was not significantly affected by 
treatment with sCR1 (t = -0.62, p > 0.5) (Fig. 4). 
Two distinct patterns of L-selectin shedding from 
the surfaces of the circulating neutrophils were 
observed. A progressive fall in L-selectin expression 
was observed in the circuits but not in the static 
loops, mirroring the change in CDllb/CD18 expres- 
sion, although the change was much less marked 
(Figs. 1 and 5). Additionally a population of neutro- 
phils emerged that had lost nearly all expression of 
L-selectin, growing progressively in number with 
time at the expense of L-selectin-positive c lls so 
that by 2 hours they numbered about 40% of the 
total (Fig. 1). Although the rate of L-selectin loss in 
the former process was significantly slower in sCR1- 
treated circuits (t = -4.51, p < 0.01) (Fig. 5), this 
difference was only apparent between 60 and 120 
minutes and the levels of expression were the same 
after 2 hours in the treated and untreated circuits 
20 
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Fig. 3. Plasma concentrations of TCC in cardiopulmo- 
nary bypass circuits. Samples were taken at 30-minute 
intervals. Results from control loops of circuit ubing held 
static are shown on right-hand side. Data are shown as 
mean plus or minus 2 standard errors. Treatment with 
sCR1 (50/xg/ml) did not modify TCC generation. 
because the neutrophils in the treated circuits had 
lower mean initial expression. The loss of L-selec- 
tin-positive cells was not affected by sCR1 (t = 0.43, 
p > 0.5) (data not shown). 
Plasma elastase-oq-antitrypsin concentrations 
rose substantially in the circuits with time and again 
showed only small changes ill static control loops 
(no sCRI: time = 0, 0.17 ± 0.02/xg/ml [mean ± 2 
SE*]; time = 120 circuits, 0.52 ± 0.22/xg/ml; time = 
120 static, 0.20 ± 0.02/xg/ml). Treatment with sCR1 
had no observed effect on release of the enzyme 
(sCRI: time = 120 circuits, 0.44 ± 0.08 /xg/ml; 
time = 120 static, 0.2 ± 0.02/xg/ml). 
IL-8 was also detected in circuits after 2 hours of 
circulation and not in static control oops (t = 4.39, 
p < 0.01). The concentrations in the plasma from 
circuits treated with sCR1 were significantly lower 
than those in untreated circuits (t = 2.49, p < 0.05) 
(Fig. 6). 
Discussion 
CR1 is a regulator of complement activation 
protein that may prove useful as an effective specific 
inhibitor of complement activation in vivo. 33 It 
*Standard error. 
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Fig. 4. Granulocyte xpression of CD11b/CD18 in car- 
diopulmonary bypass circuits. Samples were taken at 
30-minute intervals. Results from control oops of circuit 
tubing held static are shown on right-hand side. Data are 
shown as mean plus or minus 2 standard errors. Treat- 
ment with sCR1 (50 /xg/ml) did not significantly modify 
changes. ReL, Relative. 
specifically binds to both C3b and C4b, thus exhib- 
iting a capacity to displace the catalytic subunits of 
the C3 and C5 convertases of both activating enzy- 
matic pathways. It also acts as a cofactor for the 
degradation of C3b and C4b by factor I. 34 Addition- 
ally, the proteolysis of C3b and C4b releases CR1 
and allows it to recycle in the inactivation process. 
Finally, unlike those of some other regulator of 
complement activation proteins, the inhibitory ef- 
fects of CR1 are not restricted by alternative path- 
way activating surfaces, which makes it particularly 
suitable for blocking complement activation by non- 
immunologic stimuliY Recombinant sCR1 consists 
of the extracellular amino acid chain of CR1 but 
lacks the transmembrance and cytoplasmic domains. 
However, sCR1 retains the inhibitory properties of 
CRI and inhibits activation of both the classic and 
alternative pathways in vitro at concentrations 100 
times lower than those of the serum regulator of 
complement activation protein, factor H. 3s 
The data from the control (untreated) circuits cor- 
roborate our previous work with both experimental 
and clinical cardiopulmonary b pass, aS' 29, 36, 37 That is, 
profound complement activation, marked changes in 
neutrophil adhesion molecule xpression, and an in- 
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Fig. 5. Granulocyte xpression of L-selectin (L-sel.) in 
cardiopulmonary b pass circuits. Samples were taken at 
30-minute intervals. Results from control oops of circuit 
tubing held static are shown on right-hand side. Data from 
each time point are divided into two values corresponding 
to two populations een in Fig. 1 (L-selectin negative 
[neg.] and positive [pos.]). Data are omitted where mean 
number of neutrophils i less than 21. Data are shown as 
mean plus or minus 2 standard errors. Treatment with 
sCR1 (50/zg/ml) resulted in little modification i changes 
in L-selectin expression. ReL, Relative. 
crease in both plasma elastase and plasma IL-8 levels 
occurred. The apparent dissociation of C3a and TCC 
generation i  the sCRl-treated circuits was an unex- 
pected finding. Inhibition of C3a generation by sCR1 
did not alter TCC production. With conventional 
complement activation the cleavage of C5 releases 
C5b, which initiates the terminal pathway resulting in 
the formation of C5b-9. Given that sCR1 is more 
effective at disassociating the C5 compared with the C3 
convertase, for any given reduction in C3a generation 
one should see an equal if not greater reduction in C5a 
and C5b and hence C5b-9 (and SC5b-9) generation. 
This suggests that a novel method of activation of the 
terminal pathway may be occurring. Vogt and col- 
leagues 38 have previously reported irect activation of 
C5 by reactive oxygen species with the formation of a 
novel terminal complex containing oxidized C5 rather 
than C5b. We have recently demonstrated that the 
soluble TCC formed in these experiments is not con- 
ventional SC5b-9, in that it contains uncleaved C5 
(that is, it is SC5-9). We have also shown that the 
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formation of this neocomplex is not induced by oxida- 
tive damage to C5 but by shear stress-induced confor- 
mational changes in C5. The full data and detailed 
discussion of the nature of this neocomplex can found 
in a parallel report (Moat and associates, submitted for 
publication). Thus sCR1 partially inhibited conven- 
tional complement activation and anaphylatoxin gen- 
eration in this model, but high circulating levels of a 
soluble protein that was not classic SC5b-9 but that 
was recognized by the sandwich enzyme-linked immu- 
nosorbent assay for SC5b-9 were unaffected. 
What was the effect of sCR1 on neutrophil acti- 
vation in this model? The marked increase in neu- 
trophil CDllb expression was not inhibited by 
sCR1. Similarly, the phenomenon f the emergence 
of an L-selectin-negative population of cells was 
unaffected. The rate of loss of surface L-selectin by 
residual L-selectin-positive n utrophils did appear 
to be reduced by sCR1. However, careful scrutiny of 
these data reveals that the levels of L-selectin ex- 
pression in this cell population were the same after 
2 hours in the treated and untreated circuits and 
that the apparent difference was produced by a 
lower mean initial expression of L-selectin in the 
neutrophils in the sCRl-treated circuits. The rise in 
plasma elastase level observed in the untreated 
circuits was also not affected by sCR1. Given the 
effect of sCR1 on complement activation in this 
model, there are three possible explanations for 
these findings: (1) that the persisting elevation of 
plasma C3a level (and presumably that of C5a) was 
sufficient o induce maximal activation of neutro- 
phils; (2) that the generation of the soluble neoter- 
minal complex was able to induce maximal neutro- 
phil activation despite inhibition of anaphylatoxin 
generation; and (3) that other physical or humoral 
factors besides complement were responsible for 
inducing neutrophil activation in this model of car- 
diopulmonary b pass. 
The first hypothesis possible but we have pre- 
liminary unpublished ata from experiments using 
membrane oxygenators in these circuits in which we 
have been able to abolish C3a generation totally 
without modifying similar changes in neutrophil 
adhesion molecule xpression and elastase release. 
On the other hand, in another ecent study, dogs 
with congenital deficiency of C3 undergoing cardio- 
pulmonary bypass demonstrated less upregulation 
of neutrophil CDllb expression than control ani- 
mals and had less myeloperoxidase deposition i  the 
lungs. 3 With regard to the second hypothesis, al- 
though there is evidence for stimulatory effects of 
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Fig. 6. Plasma concentrations of IL-8 in cardiopulmonary 
bypass circuits. Samples were taken at 30-minute intervals. 
Results from control loops of circuit ubing held static are 
shown on right-hand side. Data are shown as mean plus or 
minus 2 standard errors. Treatment with sCR1 (50/xg/ml) 
significantly inhibited IL-8 generation i bubble circuits 
(p < 0.01). 
membrane-bound TCC on neutrophils, 39 the bio- 
logic activity of the neocomplex generated in these 
experiments is unknown and requires further study. 
Finally, other potential neutrophil-activating medi- 
ators have been described in clinical and simulated 
bypass that might explain our results, 4° as might 
direct physical interaction with the surfaces in the 
circuit: this is an attractive hypothetical explanation 
for the total stripping of L-selectin from some 
neutrophils. 
Inhibition of IL-8 generation by sCR1 is an 
interesting and unexpected finding. IL-8 is tran- 
siently detectable in the blood of children and 
adults undergoing cardiopulmonary b pass} 8'41 
The known cellular sources for IL-8 in these 
circuits would be mononuclear leukocytes and 
neutrophils. Established stimuli for the release of 
IL-8 include IL-1, tumor necrosis factor, and 
endotoxin. 42'43 Although C5a desArg did not 
induce IL-8 release when used as an inflammatory 
stimulus in a rabbit model of peritonitis, 44 a 
recent report has shown generation of IL-8 by 
monocytes stimulated with C5a. 45 IL-8 probably 
plays an important role in the regulation of 
transendothelial migration of neutrophils and 
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thus in neutrophil-mediated ndothelial and tis- 
sue injury. If this finding of inhibition of IL-8 
generation by sCR1 were reaffirmed in vivo, the 
inhibition could underlie the beneficial effect of 
sCR1 seen in experimental models of cardiopul- 
monary bypass. 46 The relationship between com- 
plement activation and IL-8 release requires fur- 
ther study. 
These results raise the question of the relevance 
of this model and the observed effects of sCR1 to 
clinical practice. These experiments only reflect 
activation of acute inflammatory pathways induced 
directly and solely by circulation of diluted, hepa- 
rinized blood through the oxygenator circuit and do 
not reflect any proinflammatory or antiinflammatory 
effects of the patient's vasculature; perhaps also for 
this reason the large fluctuations in neutrophil count 
we have reported in vivo Is were not observed. Thus 
an important advantage of this model was that we 
were able to study a fixed population of leukocytes 
over time, which could not have been done in vivo. 
Furthermore, the conditions we used, a high blood 
flow rate and no systemic ooling, were chosen to 
maximize complement activation rather than closely 
to mimic the situation in vivo, and consequently the 
plasma levels of C3a were higher than those seen in 
previous clinical studies. 27 The aim is thus to dissect 
the relationships between elements of the inflamma- 
tory response induced by oxygenator circuitry and 
allow preliminary evaluation of an agent that could 
be a candidate for future intervention. In particular, 
the apparent inhibitory effect of sCRI on IL-8 
generation could prove to be important if this 
cytokine is shown, in due course, to have a role in 
the pathophysiologic process of postbypass capillary 
leak. 
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